# $prtc

Major biotech firm announces accelerated FDA review for a novel cancer therapy, sparking significant investor interest. Meanwhile, a key pharmaceutical company faces scrutiny over manufacturing delays impacting a widely anticipated drug launch.

### About $prtc
$prtc is a digital platform focused on pharmaceutical and biotech developments.

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing